The CEO of the Newcastle Helix based business described the huge investment round as 'transformational': The CEO of the Newcastle Helix based business described the huge investment round as 'transformational' The director of Newcastle biotech business Iksuda Therapeutics has hailed a “transformational” $47m investment into the company. The Newcastle Helix based business has announced it has completed $47m (around £34m) financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners. The funding has been made to support the advancement of Iksuda’s lead assets, as well as expansion of its platform technologies.